Objectives: A Trust strategy to reduce ciprofloxacin use was implemented at a University hospital. This study aimed to investigate whether the susceptibility of Gram-negative organisms (GNO) to alternative antimicrobials (co-amoxiclav, doxycycline, aztreonam, piperacillin/tazobactam, meropenem and gentamicin) changed, and whether there was any relationship between GNO susceptibility to these antimicrobials and ciprofloxacin usage.
Introduction
Antimicrobial use has been associated with an increased prevalence of resistant organisms, with a causal relationship between usage in hospital and antimicrobial resistance. 1 -9 A Trust strategy was implemented to reduce the use of quinolones, formalized by the introduction of an antibiotic policy in July 2008. A previous strategy in 2006 had removed cephalosporins except for treatment of CNS infections.
The aim of this study was to examine antimicrobial use and resistance specifically in Gram-negative organisms (GNO) by investigating whether there was/were: (i) a demonstrable change in usage of ciprofloxacin and alternative antibiotics based on defined daily doses (DDDs) prescribed; (ii) changes in the proportion of GNO susceptible to these antibiotics; and (iii) an association between susceptibility and the usage of these antibiotics.
Methods

Study design, setting and definitions
The Royal Victoria Hospital is a 700 bed university hospital with a 28 bed intensive care unit/high-dependency unit (ICU/HDU), and regional trauma and neurosurgical services. A retrospective observational study was carried out to investigate antibiotic usage and the susceptibility of GNO using prospectively collected computerized laboratory records and pharmacy data between January 2008 and August 2009. The first isolate of each different GNO isolated from each of the following sites from all adult inpatients except maternity inpatients were included in this study: blood cultures; sputum; and urine. Reisolates of the same organism from a given site during the hospital admission were excluded.
Isolate identification and susceptibility testing
Identification and susceptibility testing were performed by either the disc diffusion method, according to the guidelines of the CLSI for susceptibility testing, 10 with API (bioMérieux, Basingstoke, UK) identification, or by the Vitek w 2 automated ID/AST system (bioMérieux, Inc., Hazelwood, MO, USA). Vitek identification was performed on blood culture isolates, isolates suspected of possessing extended-spectrum b-lactamase (ESBL) or AmpC enzymes and all isolates from ICU/HDU patients. API identification was performed on this group of isolates when Vitek identification was not possible. Lactose-fermenting aerobic Gram-negative bacilli from urine or sputum from non-ICU/HDU patients were not identified, but were reported as coliforms with disc diffusion susceptibilities provided that the isolate was not multidrug resistant carbapenem resistant or a suspected AmpC or ESBL producer based on disc diffusion susceptibilities. These susceptibility and identification methods were consistent throughout the study period.
When AmpC or ESBL enzymes were detected, isolates were categorized as resistant to cephalosporins, and aztreonam, in accordance with HPA recommendations.
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Antibiotic usage
Antibiotic usage was expressed as DDD using the WHO ATC/DDD 2009 index 12 calculated from monthly pharmacy data for all adult wards; this included both oral and intravenous preparations. Antimicrobial use was adjusted for hospital occupancy by converting total DDD to DDD/ 1000 occupied bed days (OBD). Antimicrobials included in this study were ciprofloxacin, 'other quinolones' (comprising moxifloxacin, norfloxacin, levofloxacin and ofloxacin), ceftriaxone and 'alternative antibiotics' (comprising aztreonam, piperacillin/tazobactam, meropenem, gentamicin, co-amoxiclav and doxycycline).
Statistical analysis
The trends over time in DDD/1000 OBD for the defined antimicrobials and the proportion of GNO susceptible to the defined antimicrobials, from January 2008 to August 2009, were tested using linear regression. The Durbin-Watson statistic (d) was used to test for serial autocorrelation in the linear regression of antimicrobial susceptibility against time. The Pearson correlation coefficient was used to assess the relationship between antimicrobial usage and susceptibility.
The 5% significance level was used for all tests. Analyses were performed using SPSS 11.0 for Windows w software (SPSS Inc., Chicago, IL, USA).
Results
A total of 5410 GNO isolates were included: 3580 (66%) from urine; 1517 (28%) from sputum; and 313 (6%) from blood cultures. Of these, 44.1% underwent identification to the species level, 14.2% to the genus level and 41.7% were not identified ( Table 1) .
Antimicrobial use
Antimicrobial usage at the study commencement and completion is shown in Table 2 
GNO susceptibility
The proportion of GNO susceptible to aztreonam increased significantly (1.87% susceptibility increase per month; 95% CI 1.18, 2.55; P,0.001). Furthermore, there was a statistically significant increase in the proportion testing susceptible to ciprofloxacin, piperacillin/tazobactam, meropenem and gentamicin [ciprofloxacin: 0.55% increase in susceptibility per month; 95% CI 0.38, 0.72; P,0.001; piperacillin/tazobactam: 0.18% susceptibility increase per month; 95% CI 0.03, 0.33; P¼ 0.021; meropenem: 0.27% susceptibility increase per month; 95% CI 0.08, 0.47; P ¼ 0.009; gentamicin: 0.17% susceptibility increase per month; 95% CI 0.04, 0.29; P ¼ 0.011 (Figure 2) ]. There was no significant change in the proportion of GNO susceptible to ceftriaxone (P¼ 0.48) or co-amoxiclav (P ¼0.89). Too few GNO isolates had doxycycline susceptibility tests recorded for this analysis of susceptibility to be performed. There was no evidence of serial autocorrelation for ciprofloxacin (d¼2.57), piperacillin/tazobactam (d¼ 2.31), meropenem (d¼2.07), gentamicin (d¼ 2.37) or co-amoxiclav (d¼ 2.22). Autocorrelation was detected for aztreonam (d¼ 1.10) and ceftriaxone (d¼ 1.05).
Association between GNO susceptibility and antimicrobial use
A Pearson bivariate correlation test was performed to determine whether there was an association between ciprofloxacin use and JAC GNO susceptibility to alternative antibiotics, for antimicrobials to which a change in susceptibility was detected. An inverse association was observed between ciprofloxacin use (DDD/1000 OBD) and the proportion of GNO susceptible to ciprofloxacin (r¼ 20.74, P,0.001), aztreonam (r¼ 20.65, P ¼ 0.002), meropenem (r ¼ 20.53, P ¼ 0.015) and gentamicin (r ¼ 20.48, P ¼ 0.034). There was also a suggestion of an inverse relationship between ciprofloxacin use and GNO susceptibility to piperacillin/tazobactam (r ¼ 20.36, P ¼ 0.12), though this failed to reach statistical significance (see Figure 3) . Table 3 illustrates the decrease in the proportion of isolates testing as susceptible to these antimicrobials per unit increase in ciprofloxacin DDD/1000 OBD.
Discussion
Antimicrobial stewardship, which includes resistance surveillance and infection control measures to minimize secondary spread, is key in the prevention of resistance. 13 -16 This study investigated antimicrobial use and its association with resistance following a series of measures to reduce ciprofloxacin use.
These data indicate that ciprofloxacin use decreased while aztreonam and gentamicin use increased, without a statistically significant effect on piperacillin/tazobactam, ceftriaxone, co-amoxiclav, doxycycline, 'other quinolones' and meropenem usage. Ciprofloxacin use decreased more than either gentamicin or aztreonam use increased; however, when pooled, the overall increased usage of 'alternative antimicrobials' approximated the ciprofloxacin decrease, suggesting that clinicians are not substituting one single agent for ciprofloxacin, but selecting from several alternatives.
The proportion of GNO susceptible to ciprofloxacin, gentamicin and b-lactam antibiotics (with the exception of co-amoxiclav and ceftriaxone) increased significantly during the study period.
Evidence for a causal relationship between ciprofloxacin usage and GNO susceptibility would be strengthened if these observations were repeated for data from a number of other centres; however, a cluster randomized trial with centres allocated to either withdraw ciprofloxacin or retain it would be required for a definitive answer. To directly correlate these variables from a single centre may overestimate the significance of the association.
Nonetheless, what is undisputed is that increasing GNO susceptibility to b-lactams (excluding ceftriaxone and co-amoxiclav) and gentamicin occurred concomitantly with reduced ciprofloxacin usage, despite the increased use of aztreonam. The contribution of infection control measures to the spread of resistant pathogens and, hence, resistance rates could not be accounted for, and may have contributed to the increase in susceptibility observed for a broad range of antibiotics.
The resistance of Gram-negative bacteria to fluoroquinolones is reported concomitant with their use. 17 -19 Although not all agree, studies largely suggest that removal of an antimicrobial may reverse the trend in resistance to it; success may, however, depend upon the class of antibiotic in question. 1,2,20 -22 Previous studies have demonstrated a rapid increase in fluoroquinolonesusceptible isolates of Enterobacteriaceae in both urine 18 and blood 23 upon cessation of the use of the drug, and it has been hypothesized that the speed of the reversion to susceptible strains is due to a 'fitness cost' in terms of transmissibility paid by the bacteria. 24, 25 Therefore, it is not unexpected that an increase in ciprofloxacin-susceptible isolates was detected in this study, even over a short period of investigation.
While beyond the scope of this study, there are biological explanations for quinolone use driving b-lactam and aminoglycoside susceptibility.
A study investigating antimicrobial consumption and urinary Escherichia coli resistance found a significant association between fluoroquinolone use and amoxicillin resistance, 26 and speculated that fluoroquinolone resistance in Enterobacteriaceae (e.g. plasmid-mediated qnr gene) may be transferred on the same plasmid as b-lactamase genes, such as AmpC and ESBL genes; a hypothesis borne out in other studies. 27 -29 Recent studies have elucidated a relationship between plasmid-mediated ciprofloxacin resistance and aminoglycoside resistance. A modified version of aminoglycoside acetyltransferase [encoded by aac(6 ′ )-Ib-cr], also associated with b-lactamase genes, acetylates both aminoglycosides and ciprofloxacin. 30 -34 The quinolone efflux pump (encoded by qepA) has been associated with the rmtB gene, which encodes a ribosome methyltransferase conferring resistance to all aminoglycosides. 35, 36 Although failure to identify isolates to the genus level may lead to the reduced detection of AmpC-producing organisms and, thus, the over-reporting of susceptibility to noncarbapenem b-lactams, this is unlikely to affect the results as laboratory methods were applied consistently throughout the study period. Moreover, the main objective was to examine the relationship between antimicrobial usage patterns and the Gram-negative resistogram.
Only antimicrobials that were possible substitutes for ciprofloxacin were included in this study, comprising intravenous (aztreonam, piperacillin/tazobactam, meropenem and gentamicin) and oral (co-amoxiclav and doxycycline) alternatives, reflecting both activity-spectrum and hospital antibiotic policy recommendations. Although not recommended as alternatives, 'other quinolones' (moxifloxacin, norfloxacin, levofloxacin and ofloxacin) and ceftriaxone were also included, to enable the antimicrobial usage pattern to be more clearly described.
Autocorrelation was detected in the regression of aztreonam and ceftriaxone susceptibility against time; therefore, the significance of trends in susceptibility for these two analyses may be overstated. Of the two, only the trend for aztreonam susceptibility was significant (P,0.001), so although some caution is recommended in interpreting it, the very low P value suggests that the trend is real.
A potential confounding factor to this study is the contribution of community antimicrobial use to hospital resistance trends. Northern Ireland has higher community antimicrobial usage than the rest of the UK, 37 with the use of penicillins increasing steadily since 2004, 38 and so this is unlikely to have contributed to the increased b-lactam susceptibility observed in this study.
These data demonstrate a reduced ciprofloxacin use and increased GNO susceptibility to ciprofloxacin, aztreonam, piperacillin/tazobactam, meropenem and gentamicin, despite increased aztreonam use, during the same study period. What is novel in this study is the broad-spectrum reversal in resistance trends observed when the ciprofloxacin 'selection pressure' was removed and the short time period over which this occurred.
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To our knowledge, there are no previous studies associating a reduction in fluoroquinolone use with a reversal of both b-lactam and gentamicin resistance in GNO.
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